Product Description
Mechanisms of Action: Potassium Channel Blocker, Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lebanon | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Advanz Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
- PDUFA summary: Correvio's Brinavess showed high efficacy and low rate of serious adverse events in emergency department setting data.
Highest Development Phases
Phase 4: Atrial Fibrillation
Phase 3: Atrial Flutter|Atrial Fibrillation|Ventricular Fibrillation|Cardiac Arrhythmias|Heart Failure|Stroke
Phase 2: Atrial Fibrillation|Atrial Flutter|Cardiac Arrhythmias|Stroke|Heart Failure
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01370629 |
MK-6621-049 | N/A |
Completed |
Atrial Fibrillation |
2018-04-05 |
2020-01-02 |
Patient Enrollment|Primary Endpoints|Treatments |
|
ACTRN12619001099112p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Crohn Disease|Intestinal Diseases |
None |
|||
2006-005072-40 |
2006-005072-40 | P2 |
Completed |
Atrial Fibrillation|Stroke|Cardiac Arrhythmias|Heart Failure |
2008-07-04 |
2025-07-09 |
Treatments |
|
NCT00526136 |
1235-SR-202-AF | P2 |
Completed |
Atrial Fibrillation |
None |
2022-03-12 |
||
NCT00267930 |
1235-SR-1005 | P2 |
Completed |
Atrial Flutter|Atrial Fibrillation |
None |
2022-03-12 |
Primary Endpoints|Treatments |
|
NCT04748991 |
REB20-2257 | P3 |
Not yet recruiting |
Atrial Fibrillation |
2025-01-01 |
2024-05-23 |
Primary Endpoints|Start Date|Treatments |
|
NCT01174160 |
MK-6621-010 AM4 | P3 |
Completed |
Atrial Fibrillation |
2012-09-01 |
2022-03-12 |
Primary Endpoints |
|
2010-018374-20 |
2010-018374-20 | P3 |
Completed |
Atrial Fibrillation |
2012-02-20 |
2025-06-29 |
Treatments |
|
NCT00989001 |
ACT V | P3 |
Terminated |
Atrial Fibrillation |
2010-11-01 |
2022-03-12 |
Primary Endpoints|Treatments |
|
2007-005625-29 |
2007-005625-29 | P3 |
Completed |
Heart Failure|Ventricular Fibrillation|Stroke|Atrial Fibrillation|Cardiac Arrhythmias |
2009-11-23 |
2022-03-12 |
Treatments |
|
NCT00668759 |
AVRO | P3 |
Completed |
Atrial Fibrillation |
2009-10-01 |
2022-03-12 |
Primary Endpoints |
|
NCT00281554 |
ACT 4 | P3 |
Completed |
Atrial Fibrillation |
2007-01-01 |
2022-03-12 |
||
NCT00115791 |
Cardiome 1235-0504 | P3 |
Completed |
Atrial Flutter|Atrial Fibrillation |
2005-06-01 |
2022-03-12 |
Primary Endpoints|Treatments |
|
NCT00468767 |
ACT I | P3 |
Completed |
Atrial Fibrillation |
2004-11-01 |
2022-03-12 |
||
NCT00476112 |
Scene 2 | P3 |
Completed |
Atrial Flutter |
2004-09-01 |
2022-03-12 |
Primary Endpoints|Treatments |
|
CTR20170287 |
CTR20170287 | P3 |
Not yet recruiting |
Atrial Fibrillation |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT04485195 |
RAFF4 Trial | P4 |
Completed |
Atrial Fibrillation |
2024-09-15 |
2025-04-11 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03005366 |
SELECTCARFAP | P4 |
Completed |
Atrial Fibrillation |
2023-06-01 |
2023-08-08 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2014-003641-95 |
SELECTI-CARFAP | P4 |
Active, not recruiting |
Atrial Fibrillation |
2016-08-04 |
2022-03-13 |
Treatments |
|
2012-000972-40 |
Vernakalant vs.Amiodarone Comparative Effectiveness Trial | P4 |
Terminated |
Atrial Fibrillation |
2016-02-20 |
2022-03-13 |
Treatments |
|
NCT01627106 |
MK-6621-055 | P4 |
Withdrawn |
Atrial Fibrillation |
2016-02-01 |
2022-03-12 |
Primary Endpoints|Treatments |
|
2011-000695-34 |
Verna-Ibu-AF | P4 |
Completed |
Atrial Fibrillation |
2015-05-12 |
2022-03-13 |
Treatments |
|
NCT01447862 |
Verna-Ibu-AF | P4 |
Completed |
Atrial Fibrillation |
2015-05-01 |
2019-03-19 |
Treatments |
|
NCT01646281 |
Vernakalant Versus Flecainide | P4 |
Unknown status |
Atrial Fibrillation |
2013-08-01 |
2019-03-19 |
Treatments |
|
2012-001898-90 |
Vernakalant versus flecainide: atrial contractility | P4 |
Active, not recruiting |
Atrial Fibrillation |
2013-06-25 |
2022-03-13 |
Treatments |